Affiliations: Department of Pediatric Physical Medicine and Rehabilitation, Children’s Healthcare of Atlanta, Atlanta, GA, USA
Correspondence:
[*]
Corresponding author: Joshua A. Vova, Department of Pediatric Physical Medicine and Rehabilitation, Children’s Healthcare of Atlanta, 1001 Johnson Ferry Rd, Atlanta, GA, 30342, USA. Tel.: +1 404 785 5437; E-mail: [email protected].
Abstract: Botulinum Toxin (BoNT) is widely used to treat hypertonia in pediatric patients. Although serious adverse events (AEs) occur infrequently, they can lead to significant patient morbidity and mortality. This paper will discuss potential safety risks that may affect outcomes, medical comorbidities, medication dosing, targeting techniques, and muscle morphology. It is the responsibility of the physician to discuss risks and benefits regarding the use of BoNT and mitigate risks of AEs while maximizing the effectiveness of the medication.
